Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b study involving multiple oral doses of AV-101 in healthy male and female
subjects. The safety, pharmacokinetics, and antihyperalgesic effect of AV-101 on
capsaicin-induced hyperalgesia will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
VistaGen Therapeutics, Inc.
Collaborators:
Cato Research National Institute on Drug Abuse (NIDA)